Understanding and targeting a specific type of bone cancer in children and adolescents
Official title: Dissecting and Targeting RB1-Mutant Osteosarcoma
Funded at University of Texas Hlth Sci Ctr Houston · NIH-11013830 · Data updated 2026-11-12
This study is looking at how a common bone cancer called osteosarcoma develops in kids and teens, especially those with a specific gene change, to find better ways to treat it and help improve survival rates.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $364,236 |
| NIH project number | 5R01CA246130-05 |
| Project ID | NIH-11013830 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adolescents diagnosed with osteosarcoma, particularly those with RB1 mutations.
✕Less likely to help
Patients with osteosarcoma who do not have RB1 mutations or those with other types of bone cancer may not benefit from this research.
What this research studies
This research focuses on osteosarcoma, a common bone cancer affecting children and adolescents, particularly those with mutations in the RB1 gene. The study aims to uncover the molecular mechanisms behind this cancer's development and progression, using patient-derived induced pluripotent stem cells (iPSCs) to model the disease. By investigating the roles of specific genes like RB1 and p53, the research seeks to identify new therapeutic targets and improve treatment strategies for patients with osteosarcoma. The ultimate goal is to enhance survival rates and treatment outcomes for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and improved survival rates for patients with RB1-mutant osteosarcoma.
How similar studies have gone: Previous research using patient-derived iPSCs has shown promise in modeling cancer and identifying therapeutic strategies, indicating a potential for success in this approach.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Lee, Dung-Fang — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Lee, Dung-Fang
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.